免責事項: 本サイトは、FDA、ClinicalTrials.gov、PubMed、SEC EDGAR などの公式公開データを一般参考用に集約するものであり、医学的助言、診断、治療推奨、投資助言を構成しません。

臨床試験

Safety and Clinical Performance of a Biological Matrix Used in Implant-based Breast Reconstruction

NCT: NCT05031962 · COMPLETED

NCT識別子NCT05031962
ステータスCOMPLETED
開始日2021-10-04
完了2026-09-22
SponsorMeccellis Biotech (INDUSTRY)
First posted
Last updated

概要

The general objective of the study is to confirm the medium/long-term safety and clinical performance of the CELLIS Breast membranes used in breast reconstruction and to identify emerging risks in comparison to clinical data related to other treatment modalities. The present study will be a prospective, multicentric, non-randomized and non-controlled trial involving 112 patients followed for 24 months. The study will be conducted in France in 7 investigational centres.

公式ソース

ClinicalTrials.govで見る →

データはClinicalTrials.gov APIから取得しています。最新のステータスは公式記録をご確認ください。

↑